Surrogate Markers for Hepatitis B Virus Covalently Closed Circular DNA

被引：3

作者：

Tu, Thomas ^{[1
,2
,3
]}

van Bommel, Florian ^{[4
]}

Berg, Thomas ^{[4
]}

机构：

[1] Univ Sydney, Westmead Clin Sch, Storr Liver Ctr, Westmead, NSW, Australia

[2] Univ Sydney, Westmead Inst Med Res, Fac Med & Hlth, Westmead, NSW, Australia

[3] Univ Sydney, Westmead Hosp, Marie Bashir Inst Infect Dis & Biosecur, Ctr Infect Dis & Microbiol, Westmead, NSW, Australia

[4] Univ Leipzig, Div Hepatol, Dept Med 2, Med Ctr, Leipzig, Germany

来源：

SEMINARS IN LIVER DISEASE | 2022年 / 42卷 / 03期

基金：

英国医学研究理事会;

关键词：

Covalently Closed Circular DNA; viral persistence; biomarkers; liver cancer; liver disease; CORE-RELATED ANTIGEN; SURFACE-ANTIGEN; HEPATOCELLULAR-CARCINOMA; HEPATOCYTE TURNOVER; ANTIVIRAL ACTIVITY; HBV CCCDNA; NUCLEOS(T)IDE ANALOGS; INFECTED HEPATOCYTES; PEGYLATED INTERFERON; LAMIVUDINE THERAPY;

D O I：

10.1055/a-1830-2741

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Chronic infection with the hepatitis B virus (HBV) is one of the most common causes of liver disease worldwide. Chronic HBV infection is currently incurable because of the persistence of the viral template for the viral transcripts, covalently closed circular deoxyribonucleic acid (cccDNA). Detecting changes in cccDNA transcriptional activity is key to understanding fundamental virology, determining the efficacy of new therapies, and deciding the optimal clinical management of HBV patients. In this review, we summarize surrogate circulating biomarkers that have been used to infer cccDNA levels and activity in people with chronic hepatitis B. Moreover, we outline the current shortcomings of the current biomarkers and highlight the clinical importance in improving them and expanding their use.

引用

页码：327 / 340

页数：14

共 168 条

[1] CONTROLLED SYNTHESIS OF HBSAG IN A DIFFERENTIATED HUMAN-LIVER CARCINOMA-DERIVED CELL-LINE
ADEN, DP
FOGEL, A
PLOTKIN, S
DAMJANOV, I
KNOWLES, BB
[J]. NATURE, 1979, 282 (5739) : 615 - 616
[2] Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg plus Chronic Hepatitis B Infection
Al-Mahtab, Mamun
Bazinet, Michel
Vaillant, Andrew
[J]. PLOS ONE, 2016, 11 (06):
[3] ALEXANDER J, 1976, South African Journal of Medical Sciences, V41, P89
[4] Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo
Allweiss, Lena
Volz, Tassilo
Giersch, Katja
Kah, Janine
Raffa, Giuseppina
Petersen, Joerg
Lohse, Ansgar W.
Beninati, Concetta
Pollicino, Teresa
Urban, Stephan
Luetgehetmann, Marc
Dandri, Maura
[J]. GUT, 2018, 67 (03) : 542 - +
[5] Anderson Ryan T, 2021, Clin Gastroenterol Hepatol, V19, P463, DOI 10.1016/j.cgh.2020.05.041
[6] [Anonymous], 2017, WHO GLOB HEP REP 201
[7] Extracellular Hepatitis B Virus RNAs Are Heterogeneous in Length and Circulate as Capsid-Antibody Complexes in Addition to Virions in Chronic Hepatitis B Patients
Bai, Lu
Zhang, Xiaonan
Kozlowski, Maya
Li, Weixia
Wu, Min
Liu, Jiangxia
Chen, Liang
Zhang, Jiming
Huang, Yuxian
Yuan, Zhenghong
[J]. JOURNAL OF VIROLOGY, 2018, 92 (24)
[8] ANTI CAPSID DRUGS HAP12 AND AT130 TARGET HBV CORE PROTEIN NUCLEAR FUNCTIONS
Belloni, L.
Palumbo, G. A.
Lupacchini, L.
Li, L.
Chirapu, S. Reddy
Calvo, L.
Finn, M. G.
Lopatin, U.
Zlotnick, A.
Levrero, M.
[J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S513 - S514
[9] Berke JM, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00560-17, 10.1128/aac.00560-17]
[10] In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides
Billioud, Gaetan
Kruse, Robert L.
Carrillo, Melissa
Whitten-Bauer, Christina
Gao, Dacao
Kim, Aneeza
Chen, Leon
McCaleb, Michael L.
Crosby, Jeffrey R.
Hamatake, Robert
Hong, Zhi
Garaigorta, Urtzi
Swayze, Eric
Bissig, Karl-Dimiter
Wieland, Stefan
[J]. JOURNAL OF HEPATOLOGY, 2016, 64 (04) : 781 - 789

← 1 2 3 4 5 6 7 8 9 10 →